DSC produces improved and more cost effective semiconductor materials for detectors used in medical, security and defence digital x-ray imaging. These materials have the potential to revolutionise the medical x-ray imaging market, as well as dramatically improving the screening of baggage in airports and railways, and enabling the manufacture of in-demand handheld scanners.
DSC had a strong founding team led by Dr. Arnab Basu, as Chief Executive. It includes Prof. Brian Tanner and Prof. Max Robinson, who had considerable experience in high tech start up ventures with previous IPO successes, and Dr. Ben Cantwell and Dr. Andy Brinkman with international expertise in the technology and related fields.
The diagnostic imaging market is a $70 billion industry in the
Amphion has focused principally in the
Amphion’s senior management team however played a key role for Medisense, one of the
Amphion’s investment in DSC represents the first fully external round of funding, after an earlier angel funding round by members of the management team. Other shareholders are
DSC’s initial products are in the area of Cadmium Telluride based x-ray detectors. Dr. Basu said: “Cadmium Telluride has long been accepted as the electronic x-ray detection material of choice in many key applications. We are the first in the world to develop a process for producing predictably high quality and large area material for detectors with high yields and greatly improved production economics. Our unique technology arrives as our target international markets are moving to digital detection.”
DSC is situated in the purpose-built NetPark Incubator facility at Sedgefield in